Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Guangzhou First People's Hospital, Guangzhou, Guangdong Shanxi Bethune Hospital, Taiyuan, Shanxi Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality